Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

N.D. James; N.W. Clarke; A. Cook; A. Ali; A.P. Hoyle; G. Attard; C.D. Brawley; S. Chowdhury; W.R. Cross; D.P. Dearnaley; J.S. de Bono; C. Diaz-Montana; D. Gilbert; S. Gillessen; C. Gilson; R.J. Jones; R.E. Langley; Z.I. Malik; D.J. Matheson; R. Millman; C.C. Parker; C. Pugh; H. Rush; J.M. Russell; D.R. Berthold; M.L. Buckner; M.D. Mason; AWS Ritchie; A.J. Birtle; S.J. Brock; P. Das; D. Ford; J. Gale; W. Grant; E.K. Gray; P. Hoskin; M.M. Khan; C. Manetta; N.J. McPhail; O'Sullivan J.M.; O. Parikh; C. Perna; C.J. Pezaro; A.S. Protheroe; A.J. Robinson; S.M. Rudman; D.J. Sheehan; N.N. Srihari; I. Syndikus; J.S. Tanguay; C.W. Thomas; S. Vengalil; J. Wagstaff; J.P. Wylie; MKB Parmar; M.R. Sydes

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Fiche du document

Auteurs

Date

1 août 2022

Discipline

Psychologie

Type de document

Articles

Périmètre

Publications

Langue

Anglais

Identifiants

doi: 10.1002/ijc.34018
issn: 0020-7136

Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/ijc.34018

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35411939

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1097-0215

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A1169D8AF6553

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/

Mots-clés 0

Abiraterone Acetate/therapeutic use; Aged; Androgen Antagonists/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Follow-Up Studies; Hormones; Humans; Male; Prednisolone/therapeutic use; Prednisone/therapeutic use; Prostatic Neoplasms/pathology; Prostatic Neoplasms, Castration-Resistant/drug therapy; Retrospective Studies; Treatment Outcome; abiraterone; clinical trial; hormone therapy; phase III; prostate cancer; randomised controlled trial; survival

Sujets proches En

Survival skills Survival after airplane accidents, shipwrecks, etc

Citer ce document

N.D. James et al., « Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). », Serveur académique Lausannois, ID : 10.1002/ijc.34018

Partage / Export

Résumé 0

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50-0.71; P = 0.31 × 10 -9 ) favoured SOC + AAP, with 5-years survival improved from 41% SOC-alone to 60% SOC + AAP. This was similar in low-risk (HR = 0.55; 95% CI: 0.41-0.76) and high-risk (HR = 0.54; 95% CI: 0.43-0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.

{"uri":"10.1002\/ijc.34018","creators":[{"id":"james_n_d","lastname":"James"},{"id":"clarke_n_w","lastname":"Clarke"},{"id":"cook_a","lastname":"Cook"},{"id":"ali_a","lastname":"Ali"},{"id":"hoyle_a_p","lastname":"Hoyle"},{"id":"attard_g","lastname":"Attard"},{"id":"brawley_c_d","lastname":"Brawley"},{"id":"chowdhury_s","lastname":"Chowdhury"},{"id":"cross_w_r","lastname":"Cross"},{"id":"dearnaley_d_p","lastname":"Dearnaley"},{"id":"de_bono_j_s","lastname":"de Bono"},{"id":"diaz_montana_c","lastname":"Diaz-Montana"},{"id":"gilbert_d","lastname":"Gilbert"},{"id":"gillessen_s","lastname":"Gillessen"},{"id":"gilson_c","lastname":"Gilson"},{"id":"jones_r_j","lastname":"Jones"},{"id":"langley_r_e","lastname":"Langley"},{"id":"malik_z_i","lastname":"Malik"},{"id":"matheson_d_j","lastname":"Matheson"},{"id":"millman_r","lastname":"Millman"},{"id":"parker_c_c","lastname":"Parker"},{"id":"pugh_c","lastname":"Pugh"},{"id":"rush_h","lastname":"Rush"},{"id":"russell_j_m","lastname":"Russell"},{"id":"berthold_d_r","lastname":"Berthold"},{"id":"buckner_m_l","lastname":"Buckner"},{"id":"mason_m_d","lastname":"Mason"},{"id":"ritchie_aws","lastname":"Ritchie"},{"id":"birtle_a_j","lastname":"Birtle"},{"id":"brock_s_j","lastname":"Brock"},{"id":"das_p","lastname":"Das"},{"id":"ford_d","lastname":"Ford"},{"id":"gale_j","lastname":"Gale"},{"id":"grant_w","lastname":"Grant"},{"id":"gray_e_k","lastname":"Gray"},{"id":"hoskin_p","lastname":"Hoskin"},{"id":"khan_m_m","lastname":"Khan"},{"id":"manetta_c","lastname":"Manetta"},{"id":"mcphail_n_j","lastname":"McPhail"},{"id":"o_sullivan_j_m","lastname":"O'Sullivan, J.M."},{"id":"parikh_o","lastname":"Parikh"},{"id":"perna_c","lastname":"Perna"},{"id":"pezaro_c_j","lastname":"Pezaro"},{"id":"protheroe_a_s","lastname":"Protheroe"},{"id":"robinson_a_j","lastname":"Robinson"},{"id":"rudman_s_m","lastname":"Rudman"},{"id":"sheehan_d_j","lastname":"Sheehan"},{"id":"srihari_n_n","lastname":"Srihari"},{"id":"syndikus_i","lastname":"Syndikus"},{"id":"tanguay_j_s","lastname":"Tanguay"},{"id":"thomas_c_w","lastname":"Thomas"},{"id":"vengalil_s","lastname":"Vengalil"},{"id":"wagstaff_j","lastname":"Wagstaff"},{"id":"wylie_j_p","lastname":"Wylie"},{"id":"parmar_mkb","lastname":"Parmar"},{"id":"sydes_m_r","lastname":"Sydes"}]}

Par les mêmes auteurs

{"uri":"10.1002\/ijc.34018","titles":["Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)."],"disciplines":[{"uri":"http:\/\/aurehal.archives-ouvertes.fr\/subject\/shs.psy","label":{"es":"Psicolog\u00eda","fr":"Psychologie","en":"Psychology"}}],"creators":[{"id":"james_n_d","lastname":"James"},{"id":"clarke_n_w","lastname":"Clarke"},{"id":"cook_a","lastname":"Cook"},{"id":"ali_a","lastname":"Ali"},{"id":"hoyle_a_p","lastname":"Hoyle"},{"id":"attard_g","lastname":"Attard"},{"id":"brawley_c_d","lastname":"Brawley"},{"id":"chowdhury_s","lastname":"Chowdhury"},{"id":"cross_w_r","lastname":"Cross"},{"id":"dearnaley_d_p","lastname":"Dearnaley"},{"id":"de_bono_j_s","lastname":"de Bono"},{"id":"diaz_montana_c","lastname":"Diaz-Montana"},{"id":"gilbert_d","lastname":"Gilbert"},{"id":"gillessen_s","lastname":"Gillessen"},{"id":"gilson_c","lastname":"Gilson"},{"id":"jones_r_j","lastname":"Jones"},{"id":"langley_r_e","lastname":"Langley"},{"id":"malik_z_i","lastname":"Malik"},{"id":"matheson_d_j","lastname":"Matheson"},{"id":"millman_r","lastname":"Millman"},{"id":"parker_c_c","lastname":"Parker"},{"id":"pugh_c","lastname":"Pugh"},{"id":"rush_h","lastname":"Rush"},{"id":"russell_j_m","lastname":"Russell"},{"id":"berthold_d_r","lastname":"Berthold"},{"id":"buckner_m_l","lastname":"Buckner"},{"id":"mason_m_d","lastname":"Mason"},{"id":"ritchie_aws","lastname":"Ritchie"},{"id":"birtle_a_j","lastname":"Birtle"},{"id":"brock_s_j","lastname":"Brock"},{"id":"das_p","lastname":"Das"},{"id":"ford_d","lastname":"Ford"},{"id":"gale_j","lastname":"Gale"},{"id":"grant_w","lastname":"Grant"},{"id":"gray_e_k","lastname":"Gray"},{"id":"hoskin_p","lastname":"Hoskin"},{"id":"khan_m_m","lastname":"Khan"},{"id":"manetta_c","lastname":"Manetta"},{"id":"mcphail_n_j","lastname":"McPhail"},{"id":"o_sullivan_j_m","lastname":"O'Sullivan, J.M."},{"id":"parikh_o","lastname":"Parikh"},{"id":"perna_c","lastname":"Perna"},{"id":"pezaro_c_j","lastname":"Pezaro"},{"id":"protheroe_a_s","lastname":"Protheroe"},{"id":"robinson_a_j","lastname":"Robinson"},{"id":"rudman_s_m","lastname":"Rudman"},{"id":"sheehan_d_j","lastname":"Sheehan"},{"id":"srihari_n_n","lastname":"Srihari"},{"id":"syndikus_i","lastname":"Syndikus"},{"id":"tanguay_j_s","lastname":"Tanguay"},{"id":"thomas_c_w","lastname":"Thomas"},{"id":"vengalil_s","lastname":"Vengalil"},{"id":"wagstaff_j","lastname":"Wagstaff"},{"id":"wylie_j_p","lastname":"Wylie"},{"id":"parmar_mkb","lastname":"Parmar"},{"id":"sydes_m_r","lastname":"Sydes"}]}

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Fiche du document

Mots-clés 0

Sujets proches En

Citer ce document

Métriques

Partage / Export

Résumé 0

Par les mêmes auteurs

Sur les mêmes sujets

Sur les mêmes disciplines

Exporter en